Core Viewpoint - Recently, Lai Mei Pharmaceutical, a subsidiary of Zhongheng Group, successfully won bids for multiple core products in national and Guangdong alliance drug procurement, showcasing the company's market competitiveness and laying a solid foundation for future market expansion [1][2] Group 1: National Drug Procurement - Lai Mei Pharmaceutical's Nicorandil tablets (5mg) were selected in the 11th batch of national drug centralized procurement, marking a significant entry into the mainstream medical market by 2025 [1] - The selection of Nicorandil tablets will provide strong support for sales and meet broader clinical needs, injecting new momentum into Lai Mei Pharmaceutical's high-quality development [1] Group 2: Guangdong Alliance Drug Procurement - Lai Mei Pharmaceutical achieved success in multiple rounds of Guangdong alliance drug procurement, with selected products covering various fields including anti-infective drugs, specialty medications, and basic infusion solutions [1] - The successful procurement results for drugs like Clindamycin injection and Triptorelin acetate injection further demonstrate the company's strong performance in the market [1] - In the procurement for common and chronic disease medications, Lai Mei Pharmaceutical's Cefoperazone dry suspension (50mg) was also successfully selected, enhancing drug accessibility [2] Group 3: Company Strength and Market Impact - The dual breakthroughs in national and provincial procurement reflect Lai Mei Pharmaceutical's comprehensive strength [2] - The selection of multiple products in centralized procurement accelerates the clinical accessibility of quality drugs, benefiting a wider patient population and reinforcing the company's brand influence in niche markets [2]

Core Viewpoint - ST Tian Sheng (002872.SZ) announced that its wholly-owned subsidiaries, Hubei Tian Sheng Pharmaceutical Co., Ltd. and Hunan Tian Sheng Pharmaceutical Co., Ltd., participated in the procurement of drugs including Dexamethasone in Guangdong Province, with several products proposed for selection in the upcoming procurement process [1] Group 1: Company Participation - Hubei Tian Sheng and Hunan Tian Sheng participated in the Guangdong Alliance procurement for Dexamethasone and other drugs [1] - The Guangdong Provincial Drug Trading Center published the proposed selection results for the procurement on October 10, 2025 [1] Group 2: Selected Products - Hubei Tian Sheng's products proposed for selection include: - Concentrated Sodium Chloride Injection - Clindamycin Hydrochloride Injection - Glucose Injection - Sodium Chloride Injection [1] - Hunan Tian Sheng's products proposed for selection include: - Cefoperazone Injection - Cefazolin Sodium Injection [1]

Core Viewpoint - ST Tian Sheng's subsidiaries, Hubei Tian Sheng and Hunan Tian Sheng, have participated in the procurement process for various pharmaceutical products, which may enhance their market presence and brand influence [1] Group 1: Procurement Participation - Hubei Tian Sheng and Hunan Tian Sheng are involved in the Guangdong Alliance procurement for drugs including concentrated sodium chloride injection, clindamycin hydrochloride injection, glucose injection, sodium chloride injection, and injectable cefoperazone and cefazolin sodium [1] Group 2: Potential Impact - The selection of these products for procurement is expected to expand the sales range and increase market share [1] - However, it is important to note that the procurement contracts have not yet been signed, leading to uncertainty regarding the subsequent impact on the company [1]